Answers are grounded in this paper and cite their sources.
FXIa is a promising drug target for development of effective anticoagulants with limited bleeding complications. Literature reveals a major trend in the number of patent applications over the last three years. These inhibitors exploit different approaches for target inhibition. Allosteric modulation of FXIa and biosynthetic inhibition of FXI are mechanistically unique. Despite initial results in patients undergoing knee anthroplasty as with antisense oligonucleotides, major advances should be realized, particularly with respect to pharmacokinetics, for FXI/FXIa inhibitors to enter the clinic.
No takes yet. Share an insight, caveat, or question.
Al‐Horani et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: